Upon acquiring R&D funding, we envisage ALZCOG Therapeutics as taking advantage of various new opportunities to advance medical imaging technology through the constuction of our small-animal imager prototype. Our primary target market will be research facilites and pharmaceutical companies. We intend to create an imaging modality will be considerably better spatial and temporal resolutions than with current medical imaging modalities (i.e. MRI, CT, SPECT) 
 
Therefore, we intend to build a small-animal imager capable of yielding a real-time picture of pathology--a picture much more complete than that obtainable with current imaging technology. These innovations should yield more complete pictures of complex pathology, at lower cost than with current, uni-modal techniques. Lastly, our technology is intended to aid its user in finding cures or remission of AD pathology in a much shorter time frames.